On April 29, 2024, Mindray Bio-Medical Electronics Co., Ltd. (a listed company on the GEM board of SZSE, stock code: 300760, “Mindray”) and APT Medical Inc. (a listed company on the STAR Market Board of SSE, stock code: 688617, “APT”) announced that Mindray had obtained the controlling shareholding right in APT.

Fangda represented Mindray as its legal counsel and led the whole legal process in this milestone transaction. By leveraging advantage of the firm’s cross-office integration, Fangda’s Greater Bay Area offices in Shenzhen and Hong Kong and Fangda’s Shanghai office worked together to serve Mindray and provide a full range of transaction services and legal advice.

• The transaction value was approximately RMB 6.65 billion. The transaction was the first time on the STAR Market Board that not only the first time on the STAR Market Board that an A-share listed company acquired another A-share listed company by cash but also the first time that acquisition involved the transfer of the controlling shareholder right. The transaction is also the largest M&A transaction between medical device companies in China to date in terms of transaction amount.
• The transaction was another large-scale industrial M&A transaction successfully facilitated by Fanda’s Greater Bay Area offices for top-tier industrial clients in the Greater Bay Area.

The Fangda team for this transaction was led by Corporate partners Leo LOU and MA Qiang, providing legal advice on M&A transactions and capital market regulatory matters. Antitrust partners Michael HAN and WANG Jin provided legal advice on the concentration declaration for the business operators involved in this transaction. Fund partner Candy TANG provided legal advice on fund regulation matters. Partners Allen FU and Sophia FENG provided legal advice on transaction compliance matters.